CN102440944A - Ivermectin transdermal liniment for animals - Google Patents
Ivermectin transdermal liniment for animals Download PDFInfo
- Publication number
- CN102440944A CN102440944A CN2010105141296A CN201010514129A CN102440944A CN 102440944 A CN102440944 A CN 102440944A CN 2010105141296 A CN2010105141296 A CN 2010105141296A CN 201010514129 A CN201010514129 A CN 201010514129A CN 102440944 A CN102440944 A CN 102440944A
- Authority
- CN
- China
- Prior art keywords
- ivermectin
- animal
- transdermal
- animals
- transdermal liniment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an ivermectin transdermal liniment for animals, which is prepared from medicinal liquor and ivermectin, wherein the medicinal liquor is prepared from the following components in percentage by volume: 20-40% of ethyl acetate, 2-5% of azone and 55-75% of propylene glycol; and the ratio of ivermectin to medicinal liquor is (0.5-1g):100mL. The novel transdermal accelerator selected in the formula can enhance the absorption of skin for medicines, does not have toxicity or irritation on the skin and body, does not have pharmacological action, and does not react with the medicines and other additives. The invention is simple to prepare and convenient to use, has high stability, and can achieve favorable anthelminthic effect.
Description
Technical field
The present invention relates to a kind of medicine that is used for animal, refer in particular to a kind of animal and use the ivermectin transdermal liniment.
Background technology
Transdermal drug delivery system is as a kind of no wound administration new way, and more traditional drug-supplying system can avoid medicine the first pass effect of liver and the gastrointestinal tract destruction to medicine.Transdermal drug delivery system can produce lasting, constant and controlled injection speed and blood drug level; Improve bioavailability of medicament, it has slow releasing function, can reduce administration number of times and dosage; Alleviate untoward reaction; Agents area is at body surface, and advantages such as use and interruption of the administration convenience are for providing a brand-new application method by medicine oral or injection.Parasitic disease is seriously to hinder animal husbandry development, overslaugh public health, the healthy important diseases of harm humans.At present and even in considerable time from now on, use the effective means that antiparasitic is still the control animal parasitosis.Ivermectin is the derivant of avilamycin, is the semi-synthetic Macrolide broad ectrum antibiotic from actinomyces, has the effect of stronger antibody ecto-and endoparasites, can effectively resist nematicide and arthropod (insecticide, Ticks and demodicid mite) etc.Transdermal administration is because convenient drug administration has been brought into play important function in the sick control of some poultry.
Summary of the invention
The technical problem that the present invention will solve provides a kind of animal and uses the ivermectin transdermal varnish; The present invention can overcome existing big, the problems such as dosage is wayward, waste medicinal liquid of medication area that dosage form exists that pour, and to propose that a kind of route of administration is new, effective blood drug concentration is held time long, toxic and side effects animal little and easy to use is used the ivermectin transdermal liniment.
The technical problem that the present invention will solve is realized by following scheme: a kind of animal is used the ivermectin transdermal liniment; It is characterized in that: add ivermectin by medicinal liquid and form; The component of medicinal liquid and each component percent by volume are: ethyl acetate 20%～40%, azone 2%～5%, propylene glycol 55%～75%, the ratio of ivermectin and medicinal liquid is: 0.5～1g: 100mL.
Advantage of the present invention and beneficial effect are:
1, the azone that relates in the present invention's prescription is a kind of novel skin penetration enhancer, and it can increase the percutaneous absorption of skin to many dissimilar medicines.The medicinal liquid that contains azone gets into the corium blood capillary and is absorbed through the appendages space, can effectively avoid liver to cross effect, reduces the medicine resolution ratio; Avoid the peak valley phenomenon of drug absorption process, alleviated the toxic and side effects that factors such as medicine or dosage cause, prolong effective acting time; Change the administration area; And effectively regulate dosage, reduce interindividual variation, have use simply, characteristics easily and efficiently, be more suitable for the antiparasitic control in pastoral area than other dosage form.Show that after deliberation this ivermectin transdermal is smeared dosage form can effectively kill the domestic animal endoparasite and ectoparasite, especially nematicide in the body is had good repelling and killing efficacy.It has remedied the blank of domestic veterinary drug market in some dosage form, for the control of parasitic disease provides new route of administration.
Method for using: the ivermectin transdermal liniment is the dosage form that abdominal part is smeared use.Consumption is the 0.5mg/kg body weight.
The specific embodiment
Through specific embodiment the present invention is done further detailed description below, following examples are descriptive, are not determinate, can not limit protection scope of the present invention with this.
Embodiment 1: a kind of animal is used the ivermectin transdermal liniment, prepares with following steps: weighing 0.5g ivermectin (IVM) is added in the 100mL volumetric flask, dissolves fully with ethyl acetate, obtains ivermectin solution; Add azone 3mL, propylene glycol 57mL successively, be settled to scale with ethyl acetate and stir, extremely the ivermectin powdered substance of white dissolves no naked eyes visible precipitate fully.Again with joining solution use disposable filtering with microporous membrane, process finished product after the fill.Place certain hour, have or not insoluble substance with preceding scrutiny again.
Embodiment 2: a kind of animal is used the ivermectin transdermal liniment, prepares with following steps: weighing 0.6g ivermectin (IVM) is added in the 100mL volumetric flask, dissolves fully with ethyl acetate, obtains ivermectin solution; Add azone 4mL, propylene glycol 70mL successively, be settled to scale with ethyl acetate and stir, extremely the ivermectin powdered substance of white dissolves no naked eyes visible precipitate fully.Again with joining solution use disposable filtering with microporous membrane, process finished product after the fill.Place certain hour, have or not insoluble substance with preceding scrutiny again.
Embodiment 3: a kind of animal is used the ivermectin transdermal liniment, prepares with following steps: weighing 1g ivermectin (IVM) is added in the 100mL volumetric flask, dissolves fully with ethyl acetate, obtains ivermectin solution; Add azone 5mL, propylene glycol 60mL successively, be settled to scale with ethyl acetate and stir, extremely the ivermectin powdered substance of white dissolves no naked eyes visible precipitate fully.Again with joining solution use disposable filtering with microporous membrane, process finished product after the fill.Place certain hour, have or not insoluble substance with preceding scrutiny again.
Embodiment 4: press the 0.1ml/1kg body weight with a kind of animal of the present invention with the ivermectin transdermal liniment, in the disposable administration of sheep abdominal part, it is 100% that 1%IVM contains the 7d negative conversion rate of 1 group of penetration enhancer (3 groups) after injection, and the worm's ovum slip is 58.54%.It is 80% that 0.5%IVM contains 1 group of penetration enhancer (2 groups) 7d worm's ovum negative conversion rate, and the worm's ovum slip is 43.64%.It is 80% that 0.5%IVM does not have penetration enhancer group (1 group) 7d worm's ovum negative conversion rate, and the worm's ovum slip is 36.07%, is lower than 1,2 group.
Claims (1)
1. an animal is used the ivermectin transdermal liniment; It is characterized in that: add ivermectin by medicinal liquid and form; The component of medicinal liquid and each component percent by volume are: ethyl acetate 20%～40%, azone 2%～5%, propylene glycol 55%～75%, the ratio of ivermectin and medicinal liquid is: 0.5～1g: 100mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105141296A CN102440944A (en) | 2010-10-08 | 2010-10-08 | Ivermectin transdermal liniment for animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105141296A CN102440944A (en) | 2010-10-08 | 2010-10-08 | Ivermectin transdermal liniment for animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102440944A true CN102440944A (en) | 2012-05-09 |
Family
ID=46004206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105141296A Pending CN102440944A (en) | 2010-10-08 | 2010-10-08 | Ivermectin transdermal liniment for animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102440944A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784166A (en) * | 2012-08-01 | 2012-11-21 | 青岛绿曼生物工程有限公司 | Compound ivermectin combination for treating livestock demodicid mite diseases and preparation method thereof |
| CN103330679A (en) * | 2013-07-02 | 2013-10-02 | 金陵科技学院 | Film coating agent for treating pigeon ectozoa and preparation method thereof |
| CN103494832A (en) * | 2013-09-29 | 2014-01-08 | 河南亚卫动物药业有限公司 | Compound ivermectin albendazole transdermal agent for livestock and application method thereof |
| CN104739753A (en) * | 2015-03-04 | 2015-07-01 | 内蒙古金河动物药业有限公司 | Stable oily avermectin pouring agent and preparation method thereof |
| CN107041869A (en) * | 2017-03-17 | 2017-08-15 | 河南农业大学 | A kind of long-acting cutaneous permeable agent of ivermectin and preparation method thereof |
| CN108125973A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of insecticidal preparation containing ivermectin |
| CN108125972A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of Chinese and Western compound insecticidal preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857727A (en) * | 2006-03-13 | 2006-11-08 | 新疆维吾尔自治区畜牧科学院兽医研究所 | Animal skin penetrant |
| CN101579309A (en) * | 2009-06-23 | 2009-11-18 | 天津必佳药业集团有限公司 | Anti-parasitic ivermectin transdermal solution used for livestock and preparation method thereof |
| CN101732336A (en) * | 2009-12-18 | 2010-06-16 | 华中师范大学 | Antiparasitic solution for external use |
-
2010
- 2010-10-08 CN CN2010105141296A patent/CN102440944A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857727A (en) * | 2006-03-13 | 2006-11-08 | 新疆维吾尔自治区畜牧科学院兽医研究所 | Animal skin penetrant |
| CN101579309A (en) * | 2009-06-23 | 2009-11-18 | 天津必佳药业集团有限公司 | Anti-parasitic ivermectin transdermal solution used for livestock and preparation method thereof |
| CN101732336A (en) * | 2009-12-18 | 2010-06-16 | 华中师范大学 | Antiparasitic solution for external use |
Non-Patent Citations (1)
| Title |
|---|
| 侯玉慧: "伊维菌素透皮溶液驱杀猪消化道线虫及疥螨的效果", 《黑龙江畜牧兽医》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784166A (en) * | 2012-08-01 | 2012-11-21 | 青岛绿曼生物工程有限公司 | Compound ivermectin combination for treating livestock demodicid mite diseases and preparation method thereof |
| CN103330679A (en) * | 2013-07-02 | 2013-10-02 | 金陵科技学院 | Film coating agent for treating pigeon ectozoa and preparation method thereof |
| CN103330679B (en) * | 2013-07-02 | 2015-04-29 | 金陵科技学院 | Film coating agent for treating pigeon ectozoa and preparation method thereof |
| CN103494832A (en) * | 2013-09-29 | 2014-01-08 | 河南亚卫动物药业有限公司 | Compound ivermectin albendazole transdermal agent for livestock and application method thereof |
| CN103494832B (en) * | 2013-09-29 | 2015-12-09 | 河南亚卫动物药业有限公司 | A kind of compound ivermectin albendazole transdermal agent for livestock and using method thereof |
| CN104739753A (en) * | 2015-03-04 | 2015-07-01 | 内蒙古金河动物药业有限公司 | Stable oily avermectin pouring agent and preparation method thereof |
| CN108125973A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of insecticidal preparation containing ivermectin |
| CN108125972A (en) * | 2016-11-30 | 2018-06-08 | 黎凯华 | A kind of Chinese and Western compound insecticidal preparation |
| CN107041869A (en) * | 2017-03-17 | 2017-08-15 | 河南农业大学 | A kind of long-acting cutaneous permeable agent of ivermectin and preparation method thereof |
| CN107041869B (en) * | 2017-03-17 | 2019-11-22 | 河南农业大学 | A kind of long-acting cutaneous permeable agent of ivermectin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102440944A (en) | Ivermectin transdermal liniment for animals | |
| CN103393672A (en) | Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| CN103889508A (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
| WO2007122619A3 (en) | Tto-based wide spectrum therapeutics, disinfectants & anesthetics for use in aquaculture | |
| CN101444555B (en) | Purely Chinese traditional medical film for curing oral ulcer and method for preparing same | |
| US11246841B2 (en) | Compositions and methods for treatment of erectile disfunction | |
| CN103429239A (en) | Methods for increasing reticulocyte hemoglobin content | |
| CN102188756A (en) | Preparation method of medicated slow-release degradable bone scaffold | |
| CN102274174A (en) | Oil suspension agent of benzimidazole medicine | |
| CN101623255B (en) | Artesunate nanoemulsion drug composition and preparation method thereof | |
| CN103142990B (en) | Medicine for treating animal bacterial diseases and preparation method thereof | |
| CN111514157A (en) | Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof | |
| CN102266387B (en) | Medicament for treating foot-and-mouth disease and method for producing medicament for treating foot-and-mouth disease | |
| RU2360667C2 (en) | Antibacterial medication for treatment and prevention of gastro-intestinal diseases in animals | |
| KR100367877B1 (en) | The method of preparing for urinary calculus lithiasis for reatment(crystal type) | |
| KR100645268B1 (en) | Pharmaceutical composition for animal drug | |
| CN106821975A (en) | A kind of Mo Naitaier oral liquids and its preparation method and application | |
| RU2140737C1 (en) | Agent for prophylaxis and treatment of animals with parasitic sicknesses | |
| RU2103997C1 (en) | Medicinal agent for treatment of animal disease of bacterial etiology, method of treatment of animal gastroenteric disease of bacterial etiology and methods of treatment of gynecological disease of bacterial etiology in animals | |
| RU2150272C1 (en) | Method for treating the cases of endometritis in cows | |
| RU2204389C1 (en) | Cestodocidal complex medicinal composition | |
| CN102670506A (en) | Non-oral administration for influenza antiviral medicament | |
| Dolyanovskyi et al. | Іmprovement of ointment composition for the treatment of arthritis | |
| CN101099737B (en) | Medicine for treating trypanosome disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120509 |